Compare STRO & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRO | SCLX |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.0M | 90.0M |
| IPO Year | 2018 | N/A |
| Metric | STRO | SCLX |
|---|---|---|
| Price | $16.60 | $9.27 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 8 | 1 |
| Target Price | ★ $18.88 | N/A |
| AVG Volume (30 Days) | ★ 131.7K | 80.0K |
| Earning Date | 03-12-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $105,646,000.00 | $40,360,000.00 |
| Revenue This Year | $63.08 | N/A |
| Revenue Next Year | N/A | $749.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.23 | $3.60 |
| 52 Week High | $21.25 | $34.27 |
| Indicator | STRO | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 74.44 | 27.89 |
| Support Level | $14.08 | $10.35 |
| Resistance Level | $17.33 | $12.30 |
| Average True Range (ATR) | 1.47 | 1.05 |
| MACD | 0.17 | -0.11 |
| Stochastic Oscillator | 89.28 | 6.16 |
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.